Program Information
Development of Dose Monitor Unit Calculation Using Clarkson Integration for Proton Beam Therapy Using Beam-Wobbling System
Y Nagata1*, R Kohno2 , Y Takada1 , K Hotta2 , H Yamaguchi1 , T Akimoto2 , (1) University of Tsukuba, Tsukuba, Ibaraki, (2) National Cancer Center Hospital East, Kashiwa, Chiba
Presentations
SU-E-T-263 (Sunday, July 12, 2015) 3:00 PM - 6:00 PM Room: Exhibit Hall
Purpose: The purpose of the present study is to develop a calculation method of dose-calibration-factor using Clarkson integration for proton therapy employing the wobbling system and to evaluate accuracy of the calculation by comparison between calculations and measurements.
Methods: CF and CALF stand for a dose-calibration-factor and a dose per monitor unit (MU), respectively. A measured dose-calibration-factor CFmeas is defined as a ratio of the measured dose per monitor unit in a patient-specific condition CALFpat to the measured dose per MU in a reference beam condition CALFref. The CFcalc is a product of three factors: CF1, CF2 and CF3. The CF1 and CF2 are a factor reflecting the effect of common beam delivery devices and that of patient specific devices and parameter (an aperture collimator, a range compensator and an air gap), respectively. The CF1 was obtained by interpolation using measured data. The CF2 was calculated using the Simplified Monte Carlo (SMC) method. The SMC method calculates a dose distribution by tracing individual protons and by using a measured Bragg curve in water. The CF3 representing the correction factor of field size effect was obtained by using the Clarkson integration. We compared the calculated and measured CF values for 20 prostate cases.
Results: Field size correction was found to be important. The calculations reproduce the measurement results within an error of ±2.0%, except for a few cases. The error was about –3.1% for the small field area of less than19 square centimeters.
Conclusion: We have developed a calculation method of dose-calibration-factor. Calculations agreed with measurements within ±2.0% for 90% of 20 prostate cases. Except for a small field size cases, the calculation method can be applied to determine the dose-calibration–factor for majority cases of prostate cancer.
Contact Email: